Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Pembrolizumab + CapecitabineOxaliplatin (CapeOx)(HER2 Negative ARM) or Pembrolizumab + Trastuzumab+ CapecitabineCisplatin (HER2 Positive ARM) in Metastatic GC as First-line Treatment

Next Previous
X
Search
Trial Profile

Phase II Study of Pembrolizumab + CapecitabineOxaliplatin (CapeOx)(HER2 Negative ARM) or Pembrolizumab + Trastuzumab+ CapecitabineCisplatin (HER2 Positive ARM) in Metastatic GC as First-line Treatment

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Oxaliplatin (Primary) ; Pembrolizumab (Primary) ; Trastuzumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Pharmacogenomic; Therapeutic Use

    • Most Recent Events

    • 11 Mar 2024 Planned End Date changed from 1 Mar 2023 to 1 Mar 2025.
    • 11 Mar 2024 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2022 Results (n=38) of a biomarker analysis assessing TME subtype by gene expression in patients with advanced gastric cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top